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IDENTIFYING MEDIATING VARIABLES WITH GRAPHICAL
MODELS: AN APPLICATION TO THE STUDY OF CAUSAL
PATHWAYS IN PEOPLE LIVING WITH HIV
ADRIAN DOBRA AND KATHERINE BUHIKIRE AND JOACHIM G. VOSS
Abstract. We empirically demonstrate that graphical models can be a valuable tool
in the identification of mediating variables in causal pathways. We make use of graphi-
cal models to elucidate the causal pathway through which the treatment influences the
levels of fatigue and weakness in people living with HIV (PLHIV) based on a secondary
analysis of a categorical dataset collected in a behavioral clinical trial: is weakness a
mediator for the treatment and fatigue, or is fatigue a mediator for the treatment and
weakness? Causal mediation analysis could not offer any definite answers to these
questions.
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1. Introduction
Mediating variables transmit the effect of a variable on another variable, and are key
in many scientific fields such as social sciences, public health, medicine and psychology
for assessing various causal pathways [3, 45, 38, 23]. However, in studies that involve
several outcome variables that are potentially highly correlated with each other, it is
unclear which of these outcome variables are directly influenced by a treatment variable,
and which outcome variables are indirectly influenced by the treatment variable through
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one or several mediating variables. In these situations, current statistical methods for
causal mediation analysis variables might not be helpful in determining the variables
with a potential mediator role.
Our data come from a study of the longitudinal progression of fatigue and weak-
ness in people living with HIV (PLHIV). Fatigue and weakness are closely related when
self-rated by PLHIV, and prevalence rates often exceed 50% for both symptoms regard-
less of HIV status, treatment status, or age [54, 58]. Nearly forty years into the HIV
epidemic, fatigue continues to be the most frequently reported and debilitating symp-
tom for PLHIV [18, 31, 11], and has been documented extensively with prevalence data
ranging from 30-98% among multiple samples of PLHIV [58, 31, 2, 5]. Jong et al. [31]
identified several predictors of fatigue, including unemployment and inadequate income;
combined antiretroviral therapy; and psychological factors such as anxiety and depres-
sion. Interestingly, laboratory values did not predict fatigue. Fatigue has been reported
as the most frequent side effect of antiretroviral medications and is associated with worse
health status, decreased work productivity, and increased health resource use [11]. It
interferes with antiretroviral adherence [2], and is one of several factors that predict
virologic failure independent of medication adherence measures [42].
Fatigue has been classified into normal daily fatigue, a state due to natural variations
in a persons energy expenditure and circadian rhythms [8]. Normal fatigue is resolved
within a 6-8h rest and sleep period [46]. Chronic fatigue on the other hand is hallmarked
by persistent or intermittent sensations of tiredness and weariness that last longer than
six months and are very unpredictable in duration and intensity [4]. Rest and sleep
do not resolve chronic fatigue but can rather lead to secondary fatigue resulting from
de-conditioning and altered sleep patterns [37, 44, 29].
The causal explanations of the origins of fatigue have been divided into three main
areas: 1) centrally related immune factors that change brain functions and impact cogni-
tion, mood and behavior changes [47]; 2) neuroendocrine and immune contributors [28]
– stressors to the hypothalamic-pituitary-adrenal axis, the autonomic nervous system
and the immune system – that impact how the body to responds appropriately to stress
and inflammation; and 3) peripheral factors such as mitochondrial dysfunction related
to fatigue decline in skeletal muscle function and muscle loss [24]. HIV infection, de-
conditioning, chronic inflammation and physiological and psychological side effects from
antiretroviral treatments such as poor sleep and depression, stigma and anxiety most
likely impact all three mechanisms [43, 49]. Muscle weakness in PLHIV is usually a sign
of deconditioning and frailty hallmarked by significant involuntary weight loss, increasing
slowness, and reduction in grip strength, or muscle atrophy – which means the active
loss of muscle tissue, or muscle inflammation – attack of immune cells of the muscle
fibers due to autoimmune or toxicity-related (AZT) processes, or a combination of these
factors [6, 12, 20, 52, 10, 9, 30, 50].
Episodic or persistent tiredness and exhaustion related to fatigue and weakness are
quite common, debilitating, and have major impacts on PLHIVs social, role, and emo-
tional functioning [33, 22]. Patients describe the fatigue and weakness sensations with
phrases such as “I feel the same when I wake up than when I went to sleep”; or “Ive got
to drag myself” [36]. The perception of fatigue and weakness is for many patients very
difficult to distinguish, however, when asked to rate them, they will distinguish both
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symptoms. High rates of fatigue and weakness were previously related to the HIV dis-
ease or related to side effects from antiretroviral therapies [55]. Most investigators have
not applied adequate longitudinal analytic methodologies to analyze these symptoms to-
gether to establish whether a symptom cluster of fatigue and weakness is maintained over
time in the same individuals. While fatigue and weakness may have similar sensations
and therefore are used interchangeably to describe them, they have very specific recom-
mendations to alleviate them. Practitioners strive in their conversations with patients
to better understand whether the patient is indeed suffering from fatigue and/or from
weakness. That differentiation would allow clinicians to make better recommendations
to alleviate one and/or the other symptom.
This paper contributes to a better understanding of the relationship between fatigue
and weakness in PLHIV based on a secondary analysis of a categorical dataset collected
in a behavioral clinical trial. We aim to elucidate the causal pathway through which
the treatment influences the levels of fatigue and weakness in PLHIV: is weakness a
mediator for the treatment and fatigue, or is fatigue a mediator for the treatment and
weakness? We propose a new method for identifying mediating variables, and empirically
demonstrate the value of this method to answer these questions.
2. Data description
The data used in our study consists of responses from 609 study participants from a
three-month, longitudinal, randomized, controlled trial of HIV-positive individuals. The
original study was reviewed by the Committee on the Protection of Human Subjects
at the University of California, San Francisco, which accepted the protocol [52, 56, 55].
There are four variables of interest: (1) signs and symptom checklist fatigue (SSC-F) with
four levels (0= absent, 1=mild, 2=moderate, 3=severe); (2) signs and symptom checklist
weakness (SSC-W) with four levels (0 = absent, 1=mild, 2=moderate, 3=severe); (3)
treatment (IC) with two levels (0= control group, 1 = intervention group); and (4) data
collection time (TIME) with three levels (0 = start of the study, 1 = one month, 2 = three
months). The fatigue and weakness levels were self scored by the study participants.
Out of the 609 individuals, 173 (28.41%) had only one symptom report, 138 (22.66%)
had two symptom reports, and 298 (48.93%) had three symptoms recorded. After the
removal of the records with missing values, we ended up with 1343 observations. Each
observation represents the measurements of weakness and fatigue of one individual at
one time point.
In the control group (IC=0), 53 study participants did not complain of either fatigue or
weakness at the start of the study (TIME=0), while 208 study participants experienced
symptoms consistent with fatigue or weakness or both. At one month (TIME = 1),
the corresponding number of study participants decreased to 45 and 143, while at three
months (TIME = 2), these numbers were 47 and 135, respectively. In the intervention
group (IC=1), 83 study participants did not complain of either fatigue or weakness at
the start of the study (TIME=0), while 232 study participants complained of fatigue
or weakness or both. At one month (TIME=1), the corresponding numbers of study
participants were 69 and 136, while at three months (TIME=2), these numbers were
87 and 105, respectively. With respect to gender, the sample was 195 (32.2%) male;
397 (65.19%) female; 17 (2.79%) transgender. With respect to race, the sample was 10
4 ADRIAN DOBRA AND KATHERINE BUHIKIRE AND JOACHIM G. VOSS
Table 1. Data recorded in the behavioral clinical trial. Study partic-
ipants are cross-classified by fatigue (SSC-F), weakness (SSC-W), time
point (TIME) and treatment group (IC).
IC 0 1
SSC-F TIME SSC-W 0 1 2 3 0 1 2 3
0 0 53 10 6 6 83 11 6 5
1 0 10 35 7 0 15 39 13 1
2 0 8 18 46 12 16 28 41 4
3 0 3 8 17 22 4 6 19 24
0 1 45 5 5 4 69 9 6 3
1 1 10 22 6 0 11 18 5 0
2 1 10 14 37 4 10 14 22 3
3 1 4 1 4 17 6 4 13 12
0 2 47 9 2 5 87 5 7 2
1 2 13 24 4 1 11 12 6 2
2 2 15 12 22 4 12 12 4 1
3 2 2 0 5 17 3 3 3 12
(1.64%) Asian/Pacific Islander ; 214 (35.14%) African American/black; 191 (32.36%)
Hispanic/Latino; 8 (1.31%) Native American Indian; 162 (26.60%) white/anglo (non-
Hispanic); and 24 (3.94%) other. The mean age of the study participants was 44.15
years (SD = 9.16), with a range between 20-70 years.
The 1343 observations are cross-classified with respect to SSC-F, SSC-W, TIME and
IC in a four-dimensional contingency table with 4 × 4 × 3 × 2 = 96 cells – see Table
1. In this contingency table, a cell count represents the number of observations at one
time point associated with the control or with the intervention group who had a certain
weakness and a certain fatigue level.
3. Approach
Hierarchical loglinear models [7, 1] give statistical representations of joint distributions
between two or more categorical variables without assuming that some of the variables
involved are outcomes, while the remaining variables are independent. The main ef-
fects associated with every variable are present in each loglinear model. Two loglinear
models involving the same variables may differ in terms of the interaction terms involv-
ing two, three or more variables they include. The interaction terms are included in a
loglinear model in a hierarchical manner: the presence of any higher order interaction
term requires the presence of any of the lower order interactions terms which involve a
subset of the variables present in the higher order term. The selection of the interac-
tion structure in hierarchical loglinear models is computationally very difficult due to
the exponential increase in the number of possible hierarchical loglinear models: while
there are nine models with 3 variables and 7580 models with 5 variables, there are about
5.6 × 1022 models with 8 variables [13]. Selection of hierarchical loglinear models has
been widely discussed in the statistical literature [21, 19, 1, 57]. More recent approaches
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that work well for high-dimensional sparse contingency tables involve Bayesian Markov
chain Monte Carlo (MCMC) algorithms[39, 40, 41, 13, 51, 14, 16, 15, 17].
A loglinear model is hierarchical if and only if the presence of a higher-order interaction
term requires the presence of any or all of its lower-order interaction terms [7]. The model
may not be identifiable without imposing some constraints on the interaction terms
[1]. Some hierarchical loglinear models are also graphical. The distinction between a
graphical loglinear model and a hierarchical loglinear model that is not graphical can
be easily understood by constructing an undirected graph G, with vertices B and edges
E, that is associated to a hierarchical loglinear model M [57] – see Figure 1 for an
example. Specifically, an edge e = (b1, b2) appears in G if and only if the observed
variables Xb1 and Xb2 appear together in an interaction term of M. The graph G is
called the interaction graph of model M [35]. Then M is graphical if and only if the
subsets of B that are the vertices of the complete subgraphs of G that are maximal with
respect to inclusion, are also maximal interaction terms inM [57, 35]. IfM is graphical,
the absence of an edge e = (b1, b2) in G is equivalent with the conditional independence
of variables Xb1 and Xb2 given the rest of the variables under the joint distribution for
XB. Moreover, if there is no path in G from vertex b1 to vertex b2, then b1 and b2 are in
two distinct and fully connected components of G, and the corresponding variables Xb1
and Xb2 are independent. Most importantly, for any three disjoint sets A, B and C such
that B = A ∪ B ∪ C, we say that B separates A and C in G if any path that connects
a vertex in A with a vertex in C contains at least one vertex in B. If B is a complete
subset of G (that is, if the subgraph of G induced by B does not have any missing edge),
we say that B is a separator of G, and that (A,B,C) is a weak decomposition of G [35].
If (A,B,C) is a weak decomposition of G, then XA and XB are conditional independent
given XC .
We propose the following method for the determination of mediating variables:
Step 1. Determine a graphical model that is best supported by the data.
Step 2. Determine a weak decomposition (A,B,C) of the undirected graph
associated with the graphical model determined in the first step such that the
treatment variable is the only element of set A. Then the variables that belong
to set B are candidate mediator variables.
Step 3. Establish mediation of the variables in B using criteria from causal
mediation analysis.
The last step is needed because the interaction graphs we defined above are undirected,
therefore they do not convey any structural information about the directionality of the
relationships represented by the edges of these graphs. This distinction is key in causal
inference [45].
It is possible that the hierarchical loglinear model that is best supported by the
data is not graphical. This is more likely to happen when the number of observed
variables becomes large. In these cases, we recommend explicitly restricting the search
to the class of graphical hierarchical models. Such a restriction is beneficial from a
computational point of view because fewer possible models will be considered. We
remark that our proposed method for the identification of mediating variables is not
restricted to categorical data, and can be used for datasets that involve continuous
variables, or continuous and discrete variables. The existing statistical literature has
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Table 2. Hierarchical loglinear models for SSC-W, SSC-F and TIME.
Here G2 stands for the log-likelihood ratio test statistic, and DF stands
for degrees of freedom.
Model Minimal sufficient statistics G2 DF p-value
1 [SSC-W][SSC-F][TIME] 859.80 39 0
2 [SSC-W][SSC-F,TIME] 841.50 33 0
3 [SSC-W,TIME][SSC-F] 826.73 33 0
4 [SSC-W,SSC-F][TIME] 51.86 30 0.010
5 [SSC-W,SSC-F][SSC-W,TIME] 18.79 24 0.763
6 [SSC-W,SSC-F][SSC-F,TIME] 33.56 24 0.093
7 [SSC-W,TIME][SSC-F,TIME] 808.44 27 0
8 [SSC-W,SSC-F][SSC-W,TIME][SSC-F,TIME] 14.75 18 0.679
defined rich families of graphical models that involve only continuous variables (e.g.,
Gaussian graphical models) or variables of mixed type – see, for example, [32, 34].
4. Application
We follow our proposed three step procedure to determine the mediator roles of weak-
ness and fatigue for the categorical data described in Section 2. The identification of
the most relevant interactions among SSC-F, SSC-W, TIME and IC is essential due to
the ability of hierarchical loglinear models to capture multivariate association structures
that show how weakness and fatigue evolve over time, as well as their change across
treatment groups.
4.1. Loglinear models for understanding the relationship between weakness
and fatigue over time. We begin by exploring the relationship between weakness
(SSC-W) and fatigue (SSC-F) adjusted for data collection time (TIME) without adjust-
ing for treatment (IC). To this end, we examine all possible hierarchical loglinear models
that involve SSC-W, SSC-F and TIME – see Table 2.
Only Models 5, 6 and 8 from Table 2 have a p-value associated with the log-likelihood
ratio test statistic G2 greater that 0.05, and fit the data well [7]. These three loglinear
models contain the interaction between SSC-W and SSC-F which implies that these data
provide evidence of a direct relationship between weakness and fatigue. We determine
which of these three models is best supported by the data by performing two pairwise
comparisons – see Table 3. First, we compare Models 6 and 8 by testing the null
hypothesis that there is no interaction between SSC-W and TIME, and found Model 8
to be superior to Model 6 (p-value = 0.004). We subsequently compare Models 5 and
8 by testing the null hypothesis of no interaction between SSC-F and TIME. In this
case the difference between the values of G2 of these two models was 4.04, hence we
fail to reject the null hypothesis of no interaction between SSC-F and TIME (p-value =
0.671). Thus Model 5 is best supported by the data. This model suggests that TIME
does not have a direct effect on fatigue, but it has a direct effect on weakness. Model 5
also indicates that the effect of TIME on fatigue is indirect.
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Table 3. Comparison between the three hierarchical loglinear models
for SSC-W, SSC-F and TIME that give a good fit to the data.
Comparison G2 difference DF difference p-value
Model 6 vs. Model 8 18.82 6 0.004
Model 5 vs. Model 8 4.04 6 0.671
Table 4. Hierarchical loglinear models for SSC-W, SSC-F, TIME and IC.
Model Minimal sufficient statistics G2 DF p-value
9 [SSC-W,SSC-F][SSC-W,TIME][SSC-W,IC] 67.11 68 0.507
10 [SSC-W,SSC-F][SSC-W,TIME][SSC-F,IC] 70.64 68 0.389
11 [SSC-W,SSC-F][SSC-W,TIME][SSC-W,IC][SSC-F,IC] 58.45 65 0.704
Table 5. Loglinear model selection for SSC-W, SSC-F, TIME and IC.
Comparison G2 difference DF difference p-value
Model 9 vs. Model 11 8.66 3 0.034
Model 10 vs. Model 11 12.19 3 0.007
4.2. Loglinear models for understanding the relationship between weakness
and fatigue over time as influenced by the treatment. We investigate whether the
multivariate relationships among SSC-W, SSC-F and TIME still hold when controlling
for the treatment (IC). For this purpose, we examine the fit of the three hierarchical log-
linear models that include the interactions present in Model 5 (see Table 3) together with
interactions between weakness and treatment group (Model 9), fatigue and treatment
group (Model 10), or both (Model 11). The results are summarized in Table 4.
Model 5 is nested in each of Models 9, 10 and 11, and these three models fit the data
well (p-value > 0.05). Thus the direct relationships between SSC-W and SSC-F, and
between SSC-W and TIME still hold in the presence of the intervention. A comparison
of Models 10 and 11 based on their G2 goodness-of-fit statistics leads to rejection of the
null hypothesis of no interaction between SSC-F and IC (p-value = 0.007) – see Table 5.
A similar comparison of Models 9 and 11 leads us to fail to reject the null hypothesis of
no interaction between SSC-W and IC (p-value = 0.034). As such, the loglinear model
with the best fit among the three models we considered is Model 9. This model shows
that SSC-W and SSC-F are directly related when in the presence of IC and TIME, and
that there is no direct effect of TIME and IC on fatigue. However, both TIME and IC
have an indirect effect on fatigue that is mediated by weakness.
The interaction graph associated with Model 9 is shown in Figure 1. The four variables
SSC-W, SSC-F, TIME and IC are each represented as vertices of this graph. Two vertices
are linked by an edge if Model 9 includes an interaction term between the corresponding
variables. Since Model 9 involves three pairwise interaction terms, the graph in Figure
1 has three edges. This model is graphical since each edge corresponds with a maximal
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Figure 1. Interaction graph associated with Model 9. This is the
graphical loglinear model with minimal sufficient statistics [SSC-W,SSC-
F][SSC-W,TIME][SSC-W,IC]. Each vertex of this graph corresponds with
an observed variable. Each edge of this graph corresponds with a pairwise
interaction term of Model 9.
interaction term of Model 9, namely, the three pairwise interaction terms [SSC-W,SSC-
F], [SSC-W,TIME] and [SSC-W,IC]. Since each path that connects SSC-F and TIME,
or SSC-F and IC, or TIME and IC must go through SSC-W, Model 9 is the model of
conditional independence of SSC-F, TIME and IC given SSC-W. Furthermore, each path
that connects vertex IC with vertices SSC-F or TIME must go through SSC-W, thus
({IC}, {SSC-W}, {SSC-F,TIME}) is a weak decomposition of the interaction graph in
Figure 1. Thus the interaction structure of Model 9 suggests that SSC-W is a candidate
mediator variable, and SSC-F cannot be a mediator variable.
We note that a graphical representation of Model 5 is obtained by eliminating the
vertex IC and the edge between SSC-W and IC from the graph in Figure 1. Model 5 is
also a graphical model: it is the model of conditional independence of SSC-F and TIME
given SSC-W.
4.3. Model validation. Our approach for selecting Models 5 and 9 was solely based
on the data available. While such a model selection strategy is widely used in modern
statistical literature, it potentially raises concerns related to whether the same hierar-
chical loglinear models would be selected if new samples involving the same variables
became available. In order to address this question, we design an objective procedure for
assessing the out of sample generalizability of the models we selected. This procedure
involves repeatedly sampling a fraction of the available samples, and determining the
most relevant loglinear models only based on the selected samples.
Instead of employing once again the hypothesis testing approach that led us to select-
ing Models 5 and 9, we follow a different approach for model determination. Here the
most relevant hierarchical loglinear model is considered to be the loglinear model with
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the smallest Akaike information criterion (AIC) [25]. The determination of the loglinear
model with the smallest AIC is performed in two different ways:
• Forward search: we start at the loglinear model of independence that involves
only the main effects. This model is the current model at the first iteration.
At subsequent iterations, the current loglinear model is improved by including
additional interaction terms that are not in the model such that the model is
still hierarchical. The search stops when the inclusion of additional interaction
terms does not lead to a hierarchical loglinear model with a smaller AIC.
• Backward search: we start at the saturated loglinar model that involves all pos-
sible interaction terms. This model is the current model at the first iteration.
At subsequent iterations, the current loglinear model is improved by deleting
interaction terms from the model such that the model is still hierarchical. The
search stops when the deletion of additional interaction terms does not lead to
a hierarchical loglinear model with a smaller AIC.
The forward and backward search procedures have been implemented with functions
from the R [48] package gRim [25]. We consider that we have successfully identified the
model with the smallest AIC if both the forward and the backward search lead to the
same hierarchical loglinear model. Based on all 1343 available samples, Model 5 turns
out to be the hierarchical loglinear model with the smallest AIC that involves variables
SSC-W, SSC-F and TIME. Similarly, based on all the available samples, Model 9 turns
out to be the hierarchical loglinear model with the smallest AIC that involves variables
SSC-W, SSC-F, TIME and IC. This finding supports our claim that Models 5 and 9
are the most representative hierarchical loglinear models for these data. We note that,
in Section 4.2, we selected Model 9 by considering only three candidate hierarchical
loglinear models. This shortcoming is addressed by the combined forward and backward
search methods that consider as candidates all possible hierarchical loglinear models
with 4 variables.
Does the AIC-based model selection strategy hold when only a fraction of the available
samples are used? To answer this question, for each q = 1%, 2%, . . . , 99%, we repeat the
following three steps 10000 times:
(1) Sample without replacement a proportion q of the available samples.
(2) Determine the most relevant hierarchical loglinear model that involves variables
SSC-W, SSC-F and TIME based on the samples selected at Step 1.
(3) Determine the most relevant hierarchical loglinear model that involves variables
SSC-W, SSC-F, TIME and IC based on the samples selected at Step 1.
The determination of the most relevant hierarchical loglinear model is performed based
on the forward and backward search methods as described above. When the forward and
backward search methods do not stop at the same loglinear model, no model is recorded
for that particular sampled dataset.
We objectively assess the out of sample properties of our model selection strategy
from Sections 4.1 and 4.2 by reporting the proportions of times Models 5 and 9 were
successfully identified – see Figures 2 and 3. When 50% or more samples are selected
from the available data, Model 5 is determined at Step 2 for at least 80% of times.
When 85% or more samples are selected, Model 9 is determined at Step 3 for at least
80% of times. The increased number of samples needed to recover Model 9 relative to
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Figure 2. Out of sample validation for Model 5. Each bar represents
the proportion of times based on 10000 sampled datasets Model 5 has
been identified to be the loglinear model with the smallest AIC involving
variables SSC-W, SSC-F and TIME. From left to right, the bars cor-
respond with sampling proportions of 1%, 2%, . . . , 99%. The horizontal
line shows the empirical probability 1/9 = 0.111 of selecting Model 5
at random from the set of nine hierarchical loglinear models with three
categorical variables.
the number of samples needed to recover Model 5 is consistent with the size of the set of
models they are selected from: while there are only 9 hierarchical loglinear models with
3 variables, there are 114 hierarchical loglinear models with 4 variables. If a hierarchical
loglinear model is selected at random from the pool of hierarchical loglinear models with
3 and 4 variables in the absence of any data, Model 5 is chosen with a probability of
1/9 = 0.111, and Model 9 is chosen with a probability of 1/114 = 0.0087. Figures 2
and 3 show that the probabilities of selecting Model 5 and Model 9 become significantly
higher as more samples are employed in the selection process. These findings confirm
that Models 5 and 9 are representative for the associations that exist among SSC-W,
SSC-F, TIME and IC which provides support for the generalizability of our conclusions.
4.4. Causal mediation analysis. Model 9, the model of conditional independence
of SSC-F, TIME and IC given SSC-W posits that: (i) there is no direct effect of the
treatment on fatigue; (ii) there is a direct effect of the treatment on weakness; and (iii)
there is a direct effect of weakness on fatigue. This suggest that weakness is a mediator
variable. Due to the indirect effect of the treatment on fatigue without a direct effect,
Model 9 provides evidence for the strongest type of mediation which was called full
mediation by Baron and Kenny [3].
In the sequel we want to ascertain whether we can reach the same conclusions by
employing a modeling framework for conducting causal mediation analysis. We follow
methods and algorithms from Imai et al. [26, 27] implemented in the R [48] package
mediation [53]. Their model-based causal mediation analysis builds on the procedure
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Figure 3. Out of sample validation for Model 9. Each bar represents
the proportion of times based on 10000 sampled datasets Model 9 has
been identified to be the loglinear model with the smallest AIC involving
variables SSC-W, SSC-F, TIME and IC. From left to right, the bars cor-
respond with sampling proportions of 1%, 2%, . . . , 99%. The horizontal
line shows the empirical probability 1/114 = 0.0087 of selecting Model
9 at random from the set of 114 hierarchical loglinear models with four
categorical variables.
of Baron and Kenny [3], and comprises the specification of two statistical models. The
first model is called the mediator model, and specifies the conditional distribution of the
mediator given the treatment and other pre-treatment covariates. The second model
is called the outcome model, and specifies the conditional distribution of the outcome,
given the treatment, the mediator, and the pre-treatment covariates. After these two
models are fit separately, the size of the indirect effect of the treatment on the outcome
is estimated by the average causal mediation effects (ACME), while the direct effect of
the treatment on the outcome is estimated by the average direct effects (ADE). The
sums of the indirect and the direct effects are called the total effects.
First, we estimate the causal effects of the treatment on fatigue with weakness as the
mediator variable. The mediator model is an ordinal logistic regression model of SSC-
W conditional on IC and TIME. The outcome model is an ordinal logistic regression
model of SSC-F conditional on SSC-W, IC and TIME. The results obtained with the
mediate function from the mediation R package are shown in Table 6. With a single
exception, the ACME of treatment on fatigue are statistically significant at the α = 0.05
level for the treated and the control groups. The ADE of the treatment on fatigue are
not statistically significant for both groups. However, total effects of the treatment on
fatigue are statistically significant at the α = 0.05 level. As such, the indirect effects of
the treatment on fatigue mediated by weakness are strong, while there does not seem to
be any evidence of direct effects of the treatment on fatigue.
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Table 6. Estimated causal effects of the treatment on fatigue with weak-
ness as mediator variable. The table shows nonparametric bootstrap con-
fidence intervals based on 2500 Monte Carlo draws with the percentile
method. Here ACME stands for average causal mediation effects, and
ADE stands for average direct effects.
Pr(SSC-F=0) Pr(SSC-F=1) Pr(SSC-F=2) Pr(SSC-F=3)
ACME (control) 0.0605 0.006589 -0.0268 -0.0403
2.5% 0.0294 0.000664 -0.0494 -0.0633
97.5% 0.0983 0.014627 -0.0136 -0.0174
p-value <0.0001 0.028800 0.0008 0.0008
ACME (treated) 0.0613 0.005649 -0.0275 -0.0394
2.5% 0.0297 -0.000046 -0.0507 -0.0621
97.5% 0.0988 0.013216 -0.0139 -0.0166
p-value <0.0001 0.052000 0.0008 0.0008
ADE (control) 0.00792 0.000607 -0.00267 -0.00585
2.5% -0.02325 -0.001627 -0.01370 -0.02762
97.5% 0.03867 0.002977 0.00749 0.01670
p-value 0.62320 0.644000 0.62320 0.62320
ADE (treated) 0.00866 -0.000334 -0.00342 -0.0049
2.5% -0.02544 -0.003323 -0.01734 -0.0229
97.5% 0.04271 0.001852 0.00987 0.0137
p-value 0.62320 0.633600 0.62320 0.6232
Total Effect 0.0692 0.006256 -0.0302 -0.0452
2.5% 0.0269 0.000358 -0.0568 -0.0748
97.5% 0.1196 0.013460 -0.0130 -0.0154
p-value 0.0016 0.040000 0.0032 0.0032
Second, we estimate the causal effects of the treatment on weakness with fatigue as
the mediator variables. The mediator and the outcome models are similar to the ones we
specified before with SSC-W and SSC-F replacing each other. The results are presented
in Table 7. In this case, most of the ACME, the ADE and the total effects of the
treatment on weakness are statistically significant. This suggests that the treatment has
strong direct as well as indirect effects mediated by fatigue on weakness. Baron and
Kenny [3] refer to the presence of both direct and indirect effects as partial mediation.
5. Discussion
Since fatigue and weakness may have similar sensations, PLHIV experience them
jointly, and consequently the measurements of these two symptoms are highly corre-
lated. As such, there is no surprise that a direct effect between fatigue and weakness
was identified when employing graphical loglinear models and in the causal mediation
analysis. In that regard, the two modeling frameworks led to the same expected con-
clusion. However, our causal mediation analysis did not offer any definite answer to
IDENTIFYING MEDIATING VARIABLES WITH GRAPHICAL MODELS 13
Table 7. Estimated causal effects of the treatment on weakness with
fatigue as mediator variable. The table shows nonparametric bootstrap
confidence intervals based on 2500 Monte Carlo draws with the percentile
method. Here ACME stands for average causal mediation effects, and
ADE stands for average direct effects.
Pr(SSC-W=0) Pr(SSC-W=1) Pr(SSC-W=2) Pr(SSC-W=3)
ACME (control) 0.0539 0.00148 -0.02766 -0.02774
2.5% 0.0132 -0.00603 -0.04233 -0.04571
97.5% 0.0841 0.00893 -0.00635 -0.00599
p-value 0.0048 0.78160 0.00400 0.01120
ACME (treated) 0.0570 -0.00537 -0.02933 -0.02231
2.5% 0.0140 -0.01313 -0.04507 -0.03718
97.5% 0.0887 0.00348 -0.00749 -0.00449
p-value 0.0040 0.25120 0.00400 0.01200
ADE (control) 0.0566 0.000629 -0.0245 -0.0327
2.5% 0.0253 -0.004313 -0.0396 -0.0531
97.5% 0.0915 0.004686 -0.0101 -0.0148
p-value <0.0001 0.891200 <0.0001 <0.0001
ADE (treated) 0.0597 -0.00622 -0.0262 -0.0273
2.5% 0.0264 -0.01240 -0.0421 -0.0450
97.5% 0.0961 -0.00123 -0.0112 -0.0127
p-value <0.0001 0.00560 <0.0001 <0.0001
Total Effect 0.1136 -0.00474 -0.0538 -0.0550
2.5% 0.0621 -0.01327 -0.0743 -0.0802
97.5% 0.1593 0.00361 -0.0283 -0.0299
p-value <0.0001 0.27040 <0.0001 <0.0001
the question of whether fatigue is a mediator variable for the effects of the treatment
on weakness, or whether weakness is a mediator variable for the effects of treatment on
fatigue. This is an important question because, in order to maximize the benefits of
interventions that deal with fatigue and weakness, the causal pathways through which
the proposed treatments affect the two symptoms need to be established.
Our causal mediation analysis from Section 4.4 found evidence of partial mediation
of fatigue, and also evidence of full mediation of weakness. Baron and Kenny [3] argue
that mediation is stronger when no direct effect of the treatment on the outcome is
found, but there is evidence of an indirect effect. According to this argument, we could
conclude that weakness is more likely to be a mediator than fatigue for this particular
treatment. Nevertheless, the literature on mediation analysis points out flaws in Barron
and Kenny’s criteria for establishing the strength of mediation. For example, Zhao et al.
[59] argues that the presence of a direct effect can represent evidence for the presence
of other unobserved mediators. Consequently, the absence of a direct effect should not
constitute a measure of the strength of mediation. Instead, Zhao et al. [59] propose using
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the size of the indirect effect of the treatment on the outcome as a more appropriate
measure of mediation strength. However, in this particular application, the estimated
ACME from Tables 6 and 7 do not seem to provide decisive evidence about when the
indirect effects are stronger: when weakness is the mediator, or when fatigue is the
mediator?
For these reasons causal mediation analysis was not helpful in differentiating between
weakness and fatigue as mediator variables. On the other hand, our proposed approach
which is based on learning the graphical model that is best supported by the data
provides a clearer answer to this question. The model of conditional independence of
fatigue, treatment and time given weakness we determined in Section 3 shows that
weakness is a mediator variable, and that fatigue is not a mediator variable.
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